EXPANDED ACCESS DATA IMPACT ON NDAs SHOULD BE ASSESSED BY FDA, REFORM BILL CONFERENCE REPORT STATES; "FAST TRACK" PROVISIONS CODIFY ACCELERATED APPROVAL

FDA should study the impact of compassionate use and expanded access data on NDA submissions in order to make sponsors more comfortable with the programs, the House/Senate FDA reform bill conference report directs.